Astellas Pharma Inc. (ALPMF) Stock Analysis

Astellas Pharma Inc. (ALPMF) Healthcare & Pipeline Overview

Astellas Pharma Inc. is a global pharmaceutical company specializing in prescription pharmaceuticals across key therapeutic areas like oncology, urology, and immunology. With a focus on innovation and strategic collaborations, Astellas develops and commercializes drugs such as XTANDI and PADCEV, maintaining a significant presence in the competitive pharmaceutical landscape.

What Is the Investment Thesis for ALPMF?

With a P/E ratio of 13.39 and a profit margin of 15.7%, the company demonstrates financial stability. Key growth drivers include the continued expansion of XTANDI in prostate cancer treatment and the uptake of PADCEV in urothelial cancer. The company's dividend yield of 3.26% offers an attractive return for investors. However, potential risks include patent expirations and competition from biosimilars. Astellas's strategic research alliances, such as the one with Harvard University, position it for long-term innovation and growth.

Based on FMP financials and quantitative analysis

ALPMF Key Highlights

Market capitalization of $27.7B reflects Astellas's significant presence in the pharmaceutical industry.

• P/E ratio of 13.39 indicates a reasonable valuation compared to its earnings.
• Gross margin of 77.7% demonstrates strong pricing power and efficient cost management.
• Dividend yield of 3.26% provides an attractive income stream for investors.
• Beta of 0.12 suggests low volatility compared to the broader market.

Who Are ALPMF's Competitors?

ALPMF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are ALPMF's Key Strengths?

Diverse product portfolio across multiple therapeutic areas.

• Strong research and development capabilities.
• Strategic collaborations with leading research institutions.
• Global presence and established distribution network.

What Are ALPMF's Weaknesses?

Reliance on key products like XTANDI.

• Exposure to patent expirations and generic competition.
• Dependence on regulatory approvals for new drugs.
• Limited presence in emerging markets compared to some competitors.

What Could Drive ALPMF Stock Higher?

Continued expansion of XTANDI in prostate cancer treatment.

• Uptake of PADCEV in urothelial cancer.
• Results from ongoing clinical trials for new therapies.
• Strategic collaborations with research institutions.
• Geographic expansion into emerging markets.

What Are the Key Risks for ALPMF?

Patent expirations on key drugs.

• Competition from generic and biosimilar drugs.
• Regulatory setbacks and delays in drug approvals.
• Product liability claims and litigation risks.
• Economic downturns affecting healthcare spending.

What Are the Growth Opportunities for ALPMF?

• Expansion of XTANDI: XTANDI, an androgen receptor signaling inhibitor for prostate cancer, presents a significant growth opportunity. The global prostate cancer market is projected to reach $12 billion by 2028. Astellas can capitalize on this by expanding XTANDI's indications and geographic reach. The company's ongoing clinical trials and marketing efforts will be crucial in driving future growth.
• Uptake of PADCEV: PADCEV, a treatment for urothelial cancer, offers another growth avenue. The urothelial cancer market is expected to grow as the global population ages. Astellas can increase PADCEV's market share through strategic partnerships and clinical trial advancements. The company's focus on addressing unmet needs in cancer treatment positions it well for future expansion.
• Strategic Collaborations: Astellas's strategic collaborations, such as the one with Harvard University, provide access to innovative technologies and therapeutic approaches. These collaborations can lead to the development of new drugs and therapies, driving long-term growth. The company's ability to identify and partner with leading research institutions will be critical in maintaining its competitive edge.
• Geographic Expansion: Expanding into emerging markets represents a significant growth opportunity for Astellas. These markets offer high growth potential due to increasing healthcare spending and unmet medical needs. Astellas can leverage its existing product portfolio and establish strategic partnerships to penetrate these markets. The company's focus on globalization will be essential in driving future revenue growth.
• Development of Cell Therapies: The strategic collaboration and license agreement with Minovia Therapeutics Ltd. for cell therapy programs targeting mitochondrial dysfunction presents a novel growth opportunity. As cell therapies gain traction in treating various diseases, Astellas's investment in this area could yield significant returns. This collaboration allows Astellas to explore innovative treatment modalities and expand its therapeutic offerings.

What Are ALPMF's Competitive Advantages?

• Patent protection for key drugs like XTANDI.
• Strong brand reputation and established market presence.
• Strategic collaborations with leading research institutions.
• Specialized expertise in key therapeutic areas.

What Does ALPMF Do?

Founded in 1923 and headquartered in Tokyo, Japan, Astellas Pharma Inc. has evolved into a global pharmaceutical leader. The company engages in the manufacture, marketing, import, and export of pharmaceuticals worldwide. Astellas's product portfolio includes XTANDI, an androgen receptor signaling inhibitor for prostate cancer; XOSPATA, a FLT3 inhibitor for adult patients with relapsed or refractory acute myeloid leukemia; PADCEV, a treatment for adult patients with locally advanced or metastatic urothelial cancer; Betanis/Myrbetriq/BETMIGA, a beta-3 adrenergic receptor agonist for overactive bladder; Evrenzo, an oral treatment for anemia associated with chronic kidney disease; and Prograf and Advagraf/Graceptor/ASTAGRAF, immunosuppressants used post-transplant. The company also offers treatments like mirabegron for neurogenic detrusor overactivity in pediatric patients, Vesicare for OAB treatment, Eligard for prostate cancer, Harnal/Omnic for benign prostatic hyperplasia, and Funguard/MYCAMINE, an antifungal agent. Astellas has established strategic collaborations with companies like Merck & Co., Inc., CytomX Therapeutics, Inc., and BANDAI NAMCO Entertainment Inc. to expand its research and development efforts. These collaborations enable Astellas to explore new therapeutic areas and technologies, reinforcing its commitment to addressing unmet medical needs.

What Products and Services Does ALPMF Offer?

• Develops and commercializes prescription pharmaceuticals.
• Focuses on therapeutic areas such as oncology, urology, and immunology.
• Manufactures and markets drugs like XTANDI for prostate cancer.
• Offers treatments for overactive bladder, including Betanis/Myrbetriq/BETMIGA.
• Provides immunosuppressants like Prograf and Advagraf/Graceptor/ASTAGRAF for transplant patients.
• Engages in strategic collaborations to expand research and development efforts.

How Does ALPMF Make Money?

• Develops and patents innovative pharmaceutical products.
• Conducts clinical trials to demonstrate safety and efficacy.
• Markets and sells prescription drugs through a global distribution network.
• Collaborates with other companies and research institutions to expand its product pipeline.

What Industry Does ALPMF Operate In?

Astellas Pharma Inc. operates in the global pharmaceutical industry, characterized by intense competition, stringent regulatory requirements, and continuous innovation. The market is driven by an aging population, increasing prevalence of chronic diseases, and advancements in biotechnology. Astellas competes with major pharmaceutical companies, including BMXXY (Bayer AG) and CHJTF (Chugai Pharmaceutical Co.), focusing on specialized therapeutic areas. The industry is witnessing a shift towards personalized medicine and targeted therapies, requiring companies to invest heavily in research and development.

Who Are ALPMF's Key Customers?

• Patients requiring prescription medications.
• Hospitals and clinics.
• Pharmacies.
• Healthcare providers.

Company Profile

Astellas Pharma Inc. operates in the Drug Manufacturers - General industry within the Healthcare sector. It is headquartered in Tokyo, JP. The company is led by CEO Naoki Okamura. ALPMF has traded publicly since 2010.

Return on equity for Astellas Pharma Inc. stands at 17.4%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 8.2%, showing how much profit it generates from its asset base. ALPMF trades at a trailing price-to-earnings ratio of 13.39, below the Healthcare sector average of ~21.50x. Its free cash flow yield is 13.1%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.17 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 7.5%, the inverse of the P/E and a quick read on earnings relative to price.

ALPMF Valuation & Market Position

With a $27.7B market cap, Astellas Pharma Inc. sits in the large-cap segment of the market.

Quarterly Financial Performance: Astellas Pharma Inc.

Revenue for Astellas Pharma Inc. came in at $4.14B during Q1 FY2027, a 17.5% improvement versus the preceding quarter. The company recorded net income of $915.3M, with diluted EPS of $0.51. Quarter-over-quarter revenue has been mixed, typical for a large-cap company operating in Healthcare. Across the four most recent quarters, ALPMF averaged $0.33 in diluted EPS.

Astellas Pharma Inc.'s Piotroski F-Score is 8/9, a 9-point checklist of profitability, leverage and efficiency — signaling solid underlying fundamentals. Its Altman Z-Score of 3.00 places it in the safe zone, indicating low near-term bankruptcy risk.

Astellas Pharma Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 4449.2% below estimates on average.

ALPMF Financials

ALPMF Latest News

ALPMF Analyst Consensus

ALPMF MoonshotScore

Common Questions About ALPMF (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources